-
The epidemiologic investigators of the Womens Health Initiative (WHI) report a comparison of cardiovascular events in the observational arm with 53,054 women and the clinical trial arm with 16,608 women.
-
The incidence of twins is now about 1 in 40 pregnancies, up from the 1 in 80 figure over a decade ago. Infertility treatments are almost exclusively responsible for this doubling effect.
-
Development and evaluation of novel agents to treat patients with ovarian cancer is a continuous (particularly for recurrent ovarian cancer patients) as well as curative therapy in this setting has yet to be identified.
-
Staphylococcal Toxins in Patients with Psoriasis, Atopic Dermatitis, Erythroderma, and in Healthy Control Subjects; Insulin Resistance and Risk of Congestive Heart Failure; Ciprofloxacin Interacts with Thyroid Replacement Therapy
-
Premature Ischemia
-
Beta-Blockers May Be Useful for Noncardiac Surgery; Promising New Weight Loss Drug?; Treating Shift-Work Disorder; Another Flu Vaccine Shortage?; FDA Actions
-
Symptoms of lower extremity venous disease are directly related to the degrees of visible and functional disease, but may occur even in legs that appear normal.
-
Two recent studies shed further light on the short-term use of parathyroid hormone (PTH) to enhance the treatment of osteoporosis. PTH is approved for use up to 2 years in patients with moderate-to-severe osteoporosis. The anabolic bone formation induced by PTH is largely lost after stopping therapy, but is well maintained by continued therapy with a biphosphonate. PTH may be given continuously or cyclically to enhance bone formation.
-
Women with polycystic ovaries demonstrate a definite rate of worsening glucose tolerance and conversion to type 2 diabetes mellitus.
-
The FDA has approved tigecycline, the first of a new class of antimicrobial agents. The drug is a novel parenteral antibiotic that is chemically similar to minocycline. It is active against a wide variety of bacteria that cause complicated intra-abdominal and complicated skin and skin structure infections including methicillin-resistant Staphylococcus aureus (MRSA). Tigecycline is marketed by Wyeth as Tygacil.
